Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

23.72 +0.09 (+0.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 424,621
Open 23.42
Bid (Size) 15.00 (9)
Ask (Size) 30.38 (2)
Prev. Close 23.63
Today's Range 23.11 - 23.75
52wk Range 13.92 - 28.18
Shares Outstanding 81,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry 
From Myriad Genetics, Inc.
Via Globe NewsWire

Performance

YTD
+55.44%
+55.44%
1 Month
+27.05%
+27.05%
3 Month
+54.33%
+54.33%
6 Month
+28.84%
+28.84%
1 Year
-6.39%
-6.39%

More News

Read More
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Earnings Preview For Myriad Genetics
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Participate in Upcoming Healthcare Conferences
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
From Myriad Genetics, Inc.
Via Globe NewsWire
3 Small Caps That Have Big Upside
Via MarketBeat
Topics Economy
Exposures Economy
3 Gene Editing Stocks With the Best Long-Term Potential
Via InvestorPlace
Insiders Selling DocuSign, Adobe And 2 Other Stocks
Via Benzinga
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
From Myriad Genetics, Inc.
Via Globe NewsWire
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
From Myriad Genetics, Inc.
Via Globe NewsWire
Why Shares of Myriad Genetics Dropped 24% This Week
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.